The application's broad, long-term objectives are to discover a blood test for early detection of ovarian cancer that will reduce ovarian cancer mortality through regular testing of targeted populations. Initially these populations would include women at high risk due to family history and/or presence of a BRCA1or BRCA2 mutation within the family, and all postmenopausal women where the incidence of disease is highest. The test requires high sensitivity for early stage disease and very high specificity so that few false positive tests will occur for each true positive test.
The specific aims are 1) to discover high probability candidate biomarkers through proteomic analysis of biofluids from three sources a) ovarian cyst fluid from benign and malignant ovarian disease, b) conditioned media from fresh sliced washed normal and malignant tissue, and c) conditioned media from phenocopy model fallopian tube systems, 2) discover high probability candidate biomarkers from genomic analysis using Affymetrix arrays of normal fallopian tube, normal ovarian, and ovarian malignant tissue lysate filtered by a comprehensive list of secreted proteins from ovarian tissue (secretome), 3) prioritize candidate biomarkers for verification by analysis of pathways from ovarian cancer pathogenesis, 4) construct mass spectrometric assays for the top 50 candidates and measure these candidates in plasma from 100 cases and 100 benign controls, and in longitudinal plasma in cases prior to clinical detection, and in controls from an ovarian cancer screening trial, and 5) determine which candidates have earliest sensitivity by estimating the change-point (if any) at which the candidate rises significantly above baseline. The five best candidates will form a biomarker panel for further testing and refinement, outside the scope of this application, in the biorepositories of larger scale screening studies.

Public Health Relevance

to public health: This research may lead to a screening test for ovarian cancer with subsequent reduction in ovarian cancer mortality. Ovarian cancer is highly curable if discovered while in early stage disease when it is confined to the ovaries. A screening test may lead to fewer ovarian cancer cases being discovered in late stage disease and thus may reduce the rate at which women die of ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA152990-03
Application #
8307487
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Patriotis, Christos F
Project Start
2010-09-24
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
3
Fiscal Year
2012
Total Cost
$701,365
Indirect Cost
$231,748
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:
Perets, Ruth; Drapkin, Ronny (2016) It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. Cancer Res 76:10-7
Wang, Suming; Blois, Anna; El Rayes, Tina et al. (2016) Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci Transl Med 8:329ra34
Skates, Steven J (2016) EPIC Early Detection of Ovarian Cancer. Clin Cancer Res 22:4542-4
Jacobs, Ian J; Menon, Usha; Ryan, Andy et al. (2016) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387:945-56
Kuhn, Eric; Carr, Steven A (2016) Multiplexed Immunoaffinity Enrichment of Peptides with Anti-peptide Antibodies and Quantification by Stable Isotope Dilution Multiple Reaction Monitoring Mass Spectrometry. Methods Mol Biol 1410:135-67
Elias, Kevin M; Emori, Megan M; Westerling, Thomas et al. (2016) Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight 1:
Jacobs, Ian J; Parmar, Mahesh; Skates, Steven J et al. (2016) Ovarian cancer screening: UKCTOCS trial - Authors' reply. Lancet 387:2603-4
Schully, Sheri D; Carrick, Danielle M; Mechanic, Leah E et al. (2015) Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst 107:
Labidi-Galy, S I; Clauss, A; Ng, V et al. (2015) Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene 34:373-83

Showing the most recent 10 out of 41 publications